Company
InMode
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
0
510(k), De Novo and PMA
Device trials
25
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
0
One per recalled product
InMode is on our public-company list (ticker INMD). Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
INMD
Nasdaq · InMode Ltd.
Public float
Unknown
Not reported in US filings
Revenue
$370M
Fiscal year ending Dec 31, 2025
Net income
$93.8M
Fiscal year ending Dec 31, 2025
R&D spending
$13.3M
Fiscal year ending Dec 31, 2025
Cash
$303M
As of Dec 31, 2025
Long-term debt
Not reported
Shares outstanding
63.4M
As of Dec 31, 2025
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
No 510(k), De Novo or PMA decisions under this name since 2015.
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Safety and Efficacy of Radio Frequency for the Treatment of Mild to Severe Inflammatory AcneCompleted
NCT05830968 · 46 participants · Start May 1, 2023 · Primary completion May 1, 2025
Device: Morpheus8 Applicator Radiofrequency device · For: Inflammatory Acne Vulgaris
Sites: Oro Valley, Arizona; Greenwood Village, Colorado; New York, New York · 4 sites in all
NCT06283056 · 48 participants · Start Jun 16, 2022 · Primary completion Oct 2, 2024
Device: Device treatment · For: Cellulitis of Leg
Sites: New York, New York; Dallas, Texas
NCT04124419 · 20 participants · Start Jul 19, 2019 · Primary completion May 19, 2021
Device: Treatment with Evolve System · For: Non-invasive Circumference Reduction
Sites: Reno, Nevada; New York, New York
22 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.